Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)

References

• Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017 May;49(5):526–535.
   PubMed Web of Science ®Google Scholar
• Srinivas P, Rivard K. Polymyxin Resistance in Gram-negative Pathogens. Curr Infect Dis Rep. 2017 Sep 11;19(11):38.
   PubMed Web of Science ®Google Scholar
• Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279–1291.
   PubMed Web of Science ®Google Scholar
• Koyama Y. A new antibiotic ‘colistin’ produced by spore-forming soil bacteria. J Antibiot. 1950;3:457–458.
   Google Scholar
• Groisman EA, Kayser J, Soncini FC. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol. 1997 Nov;179(22):7040–7045.
   PubMed Web of Science ®Google Scholar
• El-Sayed Ahmed MAE-G, Zhong -L-L, Shen C, et al. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect. 2020;9(1):868–885.
   PubMed Web of Science ®Google Scholar
• Nation RL, Velkov T, Li J. Colistin and Polymyxin B: peas in a Pod, or Chalk and Cheese? Clinl Infect Dis. 2014;59(1):88–94.
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004 May;53(5):837–840.
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, et al. Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: implications for Selection of Dosage Regimens. Clinl Infect Dis. 2013;57(4):524–531.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacother J Human Pharmacol Drug Ther. 2019;39(1):10–39.
   Google Scholar
• Oliota AF, Penteado ST, Tonin FS, et al. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019 May 1;94(1):41–49.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017 Feb 1;49(2):233–238.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS); 2018 [updated 4 Jun 2018; cited 2020 10 Sept]. Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers
   Google Scholar
• US Food & Drug Administration. FDA FAERS Data Dictionary; 2015 [updated Jan 2015; cited 2020 9 Sept]. Available from: https://pharmahub.org/app/site/resources/2018/01/00739/FDA-FAERS-Data-Dictionary.pdf
   Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations; 2020 [updated Sept 2020; cited 2020 Sept 2020]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
   Google Scholar
• US Food & Drug Administration. National Drug Code Directory; 2020 updated 10 Sept 2020; cited Sept 10 2020]. Available from: https://www.accessdata.fda.gov/scripts/cder/ndc/index.cfm
   Google Scholar
• IBM Micromedex®. 2020 [cited 2020 Mar 20]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian
   Google Scholar
• Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3):e02319–16.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. CFR – Code of Federal Regulations Title 21; 2019 [updated 1 Apr 2019; cited 2020 10 Sept 1 Apr 2019]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm
   Google Scholar
• MedDRA- Medical Dictionary for Regulatory Activities. MedDRA Version 23.0; 2020 [updated March/April 2020; cited 2020 Sept 10]. Available from: https://www.meddra.org/how-to-use/support-documentation/english
   Google Scholar
• Wertheim H, Van Nguyen K, Hara GL, et al. Global survey of polymyxin use: a call for international guidelines. J Glob Antimicrob Resist. 2013;1(3):131–134.
   PubMed Web of Science ®Google Scholar
• Tran TB, Velkov T, Nation RL, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016 Dec;48(6):592–597.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014 Apr;43(4):349–352.
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, et al. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis. 2009 Dec;65(4):431–434.
   PubMed Web of Science ®Google Scholar
• Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin b in critically Ill patients at a tertiary care medical center. Clinl Infect Dis. 2013;57(9):1300–1303.
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–2746.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Antimicrob Agents Chemother. 2016 Apr;60(4):2443–2449.
   PubMed Web of Science ®Google Scholar
• Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015;70(6):1903–1907.
   PubMed Web of Science ®Google Scholar
• Ordooei Javan A, Shokouhi S, Sahraei Z, et al. Nephrotoxicity of high and conventional dosing regimens of colistin: a randomized clinical trial. Iran J Pharm Res. 2017 Spring;16(2):781–790.
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist. 2017;10:293–298.
   PubMed Web of Science ®Google Scholar
• Crass RL, Rutter WC, Burgess DR, et al. Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin b compared to colistin. Antimicrob Agents Chemother. 2017;61(4): Apr.
   PubMed Web of Science ®Google Scholar
• John JF, Falci DR, Rigatto MH, et al. Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B. Antimicrob Agents Chemother. 2018;62(1):Jan.
   Web of Science ®Google Scholar
• Elefritz JL, Bauer KA, Jones C, et al. Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically Ill patients with multidrug-resistant gram-negative pneumonia. J Intensive Care Med. 2017 Sep;32(8):487–493.
   PubMed Web of Science ®Google Scholar
• Shields RK, Anand R, Clarke LG, et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS One. 2017;12(3):e0173286.
   PubMed Web of Science ®Google Scholar
• Bellos I, Pergialiotis V, Frountzas M, et al. Efficacy and safety of colistin loading dose: a meta-analysis. J Antimicrob Chemother. 2020;75(7):1689–1698.
   PubMed Web of Science ®Google Scholar
• Roberts KD, Azad MAK, Wang J, et al. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin b and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria. ACS Infect Dis. 2015 Nov 13;1(11):568–575.
   PubMed Web of Science ®Google Scholar
• Phe K, Shields RK, Tverdek FP, et al. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016;71(12):3585–3587.
   PubMed Web of Science ®Google Scholar
• Lafrance J-P, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21(2):345–352.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Dewanji A. Effect of reporting bias in the analysis of spontaneous reporting data. Pharm Stat. 2015;14(1):20–25. Jan-Feb.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Voulgaris GL, Samonis G, et al. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018 Jan 1;51(1):1–9.
   PubMed Web of Science ®Google Scholar
• Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis*. Crit Care Med. 2015;43:3.
   PubMed Web of Science ®Google Scholar
• Solé-Lleonart C, Rouby JJ, Blot S, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology. 2017 May;126(5):890–908.
   PubMed Web of Science ®Google Scholar